BioLargo Relaunching CupriDyne(R)-Based Consumer Products - Back by Popular Demand and Generated More than $125 Million in Pet-Care Sales

Rhea-AI Summary

BioLargo (OTCQX:BLGO) announced the formation of subsidiary BioLargo CPG to relaunch CupriDyne®-based consumer pet products under a new, yet-to-be-named brand. The move follows the marketing success of CupriDyne products previously licensed to Pooph, which generated more than $125 million in pet-care sales.

BioLargo plans a digital-first strategy, selling direct-to-consumer and via online marketplaces such as Amazon, and intends to expand from pet odor control into broader household odor and cleaning products. According to Grand View Research, the U.S. pet odor control and clean-up market was about $6.47 billion in 2023, projected to reach $8.87 billion by 2030. Management highlights that BioLargo will now own the brand and control marketing and distribution.

Positive

• CupriDyne pet products previously generated over $125 million in licensed sales
• Target market size about $6.47B (2023), projected to $8.87B by 2030
• BioLargo will own the new brand and control marketing and distribution
• Plans for digital-first sales, including direct-to-consumer and Amazon channels

Negative

• None.

News Explained

Ownership and distribution control would move in-house, but the disclosure remains at pre-launch preparation.

The July 13 release says BioLargo has formed BioLargo CPG and is preparing to relaunch CupriDyne-based pet products under a brand not yet announced.

This would shift the consumer-product setup from prior licensed sales to a BioLargo-owned brand sold directly and through online marketplaces, with BioLargo controlling marketing and distribution.

Despite the headline’s “Relaunching” wording, the body says the company is preparing the products and will provide the brand and product-line details as formal launch nears, so the disclosed state is pre-launch preparation rather than a completed launch.

BioLargo says CupriDyne-based pet products generated more than $125 million in sales while licensed and marketed as Pooph; the release presents that as historical sales under the prior brand while describing the new line as not yet launched.

The next disclosed milestones are the formal launch and release of the product line, brand name, and key team-member information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne^® technology under its own brand following the marketing success of the original Pooph products that generated more than $125 million in pet-care sales while under license from BioLargo.

WESTMINSTER, CA / ACCESS Newswire / July 13, 2026 / BioLargo, Inc. (OTCQX:BLGO) today announced that it is preparing to relaunch CupriDyne^®-based consumer pet products under a yet-to-be-announced brand. Targeting pets first, the new consumer products subsidiary will eventually expand into household odor and cleaning products. Formed to fill the gap left by Pooph's ongoing withdrawal from the market, BioLargo will sell direct to consumers and through online marketplaces such as Amazon, leveraging a "digital-first" strategy that allows for hyper-specific audience targeting, real-time performance tracking, and flexible budgets, rather than depending on expensive television campaigns.

CupriDyne-based pet products generated over $125 million in sales while under license and marketed under the Pooph brand. Unfortunately, a series of business decisions by Pooph's management later culminated in its abandonment of CupriDyne-formulated products, the foreclosure of their assets by their lender, board and CEO resignations, and what appears to be the cessation of business operations. BioLargo always owned the CupriDyne technology and had to revoke Pooph's license. Now, the ownership of the Pooph brand is embroiled in litigation. "As a result, we have an opportunity to leverage the prior marketing success by introducing our own brand" said Joseph Provenzano, who will lead the new BioLargo consumer products subsidiary as CEO.

BioLargo's launch brings the CupriDyne^® technology and BioLargo's original products back to consumers who loved them. According to Grand View Research¹, the U.S. pet odor control and clean-up products market was valued at approximately $6.47 billion in 2023 and is projected to reach approximately $8.87 billion by 2030. BioLargo's initial launch into pet odor control is part of a much larger home and pet cleaning opportunity. The company views pet care as a proven, well-defined category where the difference between masking and eliminating odors is immediately obvious to consumers. Unlike the Pooph brand, BioLargo's new brand will not be limited to pets, and will use the pet product launch to anchor a broader expansion of CupriDyne products across the home.

BioLargo has assembled a team of branding, marketing, creative, and channel-sales experts with proven track records building and growing consumer brands nationally in the pet and household categories. It plans to release additional information, including the product line, the brand name, and key team members, as the product nears its formal launch.

"It will be great to get back into the pet odor control and consumer products business", said Dennis Calvert, BioLargo CEO. "We have seen what can be done, and this time we will own the brand and control the marketing and distribution."

About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

CONTACT:

Investor Relations
Matt Kreps
Darrow Associates, Inc.
214-597-8200
mkreps@darrowir.com

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
info@BioLargo.com

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

¹ Grand View Research (2004), U.S. Pet Odor Control & Clean-up Products Market(2024 - 2030) https://www.grandviewresearch.com/industry-analysis/us-pet-odor-control-clean-up-products-market-report

SOURCE: BioLargo, Inc

View the original press release on ACCESS Newswire

FAQ

What did BioLargo (OTCQX:BLGO) announce on July 13, 2026 about CupriDyne consumer products?

BioLargo announced it is relaunching CupriDyne-based consumer pet products under a new brand through its BioLargo CPG subsidiary. According to BioLargo, this follows earlier licensed products that generated more than $125 million in pet-care sales under the Pooph brand.

How successful were CupriDyne-based Pooph pet products before BioLargo’s relaunch (BLGO)?

CupriDyne-based pet products generated more than $125 million in sales while licensed and marketed under the Pooph brand. According to BioLargo, this prior performance supports relaunching its own brand using the same CupriDyne technology directly for consumers.

What is BioLargo CPG’s go-to-market strategy for the new CupriDyne pet products?

BioLargo CPG plans a digital-first strategy, selling direct-to-consumer and via online marketplaces like Amazon. According to BioLargo, this approach emphasizes targeted audiences, real-time performance tracking, and flexible budgets instead of depending on expensive television advertising campaigns.

How large is the pet odor control market targeted by BioLargo’s CupriDyne relaunch (BLGO)?

The U.S. pet odor control and clean-up market was about $6.47 billion in 2023 and could reach $8.87 billion by 2030. According to BioLargo, its CupriDyne relaunch targets this segment as part of a broader home and pet cleaning opportunity.

Will BioLargo’s new CupriDyne brand extend beyond pet odor control for BLGO investors?

Yes, BioLargo plans to start with pet odor control, then expand to household odor and cleaning products. According to BioLargo, the pet line will anchor a broader rollout of CupriDyne-based products across the home under the new brand.

How does owning the brand benefit BioLargo in the CupriDyne product relaunch?

BioLargo states it will now own the brand and control marketing and distribution for CupriDyne-based products. According to BioLargo, this contrasts with prior licensing and allows direct oversight of strategy, channels, and execution in the consumer market.